Podcast: Improving Communication – The Relationship Between Biotech And Pharma

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

"My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” 

In this latest instalment of the In Vivo podcast, Treehill Partners founder, CEO and chair Ali Pashazadeh focuses on the need for increased communication between biotech and pharma and their contract organizations (both research and development/manufacturing organizations). Pashazadeh also analyzes how his previous medical experience guides him now, as he attempts to transfer the same ethos held as a doctor and clinician to the world of investment banking.

Timestamps:

  • Introduction - 00:00
  • Clinal development optimization model - 2:37
  • Transferring between industries – 7:06
  • To what extent will AI impact research? - 11:56
  • China and the importance of early data - 15:23
  • Looking ahead - 16:35  
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Deal-Making

Deals Shaping The Industry, August 2024

 
• By 

<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>

Innovative Drugs: China Gains Deals, But Financing Amounts Drop

 
• By 

China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”

Deal Volume Up, Value Down During The First Half

 
• By 

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals Shaping The Industry, July 2024

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting